Immunotherapy with ponezumab for probable cerebral amyloid angiopathy.
Adult
Aged
Aged, 80 and over
Alzheimer Disease
/ complications
Amyloid beta-Peptides
/ metabolism
Antibodies, Monoclonal, Humanized
/ therapeutic use
Cerebral Amyloid Angiopathy
/ complications
Cerebral Hemorrhage
/ drug therapy
Double-Blind Method
Female
Humans
Immunologic Factors
/ therapeutic use
Immunotherapy
/ methods
Magnetic Resonance Imaging
/ methods
Male
Middle Aged
Peptide Fragments
/ metabolism
Treatment Outcome
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
15
01
2019
revised:
19
02
2019
accepted:
20
02
2019
entrez:
26
4
2019
pubmed:
26
4
2019
medline:
26
4
2019
Statut:
epublish
Résumé
Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of Thirty-six participants aged 55-80 years with probable CAA received intravenous placebo ( The mean change from baseline to Day 90 was 0.817 (ponezumab) and 0.958 (placebo): a mean ratio of 0.852 (90% CI 0.735-0.989) representing a trend towards Ponezumab was safe and well-tolerated. The ponezumab group showed a trend towards treatment effect at Day 90 that was opposite to the hypothesized direction. The prespecified efficacy criteria were thus not met.
Identifiants
pubmed: 31020004
doi: 10.1002/acn3.761
pii: ACN3761
pmc: PMC6469253
doi:
Substances chimiques
Amyloid beta-Peptides
0
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
Peptide Fragments
0
amyloid beta-protein (1-40)
0
ponezumab
1TG15H1XE9
Types de publication
Journal Article
Langues
eng
Pagination
795-806Investigateurs
Charlotte Cordonnier
(C)
David John Werring
(DJ)
Sandra Elizabeth Black
(SE)
Lawrence Sterling Honig
(LS)
Catharina Jm Klijn
(CJ)
Jin-Moo Lee
(JM)
Lucas Restrepo
(L)
Carlos Kase
(C)
Sean I Savitz
(SI)
Déclaration de conflit d'intérêts
Claire Leurent, James A. Goodman, Yao Zhang, Ping He, Monica Lindsay, Linda Frattura, U. S. Sohur, and Martin M. Bednar were employees of Pfizer. Steven M. Greenberg served as a consultant to Pfizer and GlaxoSmithKline and on safety monitoring committees for amyloid immunotherapy studies conducted by Roche, Biogen, and DIAN‐TU. Massachusetts General Hospital participated in this study under a Clinical Research Support Agreement with Pfizer. Anand Viswanathan served on safety monitoring committees for amyloid immunotherapy studies conducted by Roche.
Références
Neurology. 2001 Feb 27;56(4):537-9
pubmed: 11222803
Ann Neurol. 2004 Feb;55(2):250-6
pubmed: 14755729
J Neuroinflammation. 2004 Dec 08;1(1):24
pubmed: 15588287
J Neurosci. 2006 May 17;26(20):5340-6
pubmed: 16707786
Brain. 2008 Dec;131(Pt 12):3299-310
pubmed: 18953056
Neurology. 2010 Apr 27;74(17):1346-50
pubmed: 20421578
Alzheimers Dement. 2010 May;6(3):212-20
pubmed: 20451869
Hum Pathol. 2010 Nov;41(11):1601-8
pubmed: 20688356
Ann Neurol. 2011 Feb;69(2):320-7
pubmed: 21387377
Alzheimers Dement. 2011 Jul;7(4):367-85
pubmed: 21784348
Brain. 2011 Aug;134(Pt 8):2376-86
pubmed: 21841203
Ann Neurol. 2011 Nov;70(5):774-80
pubmed: 22162060
Ann Neurol. 2011 Dec;70(6):871-80
pubmed: 22190361
Ann Neurol. 2012 Jul;72(1):76-81
pubmed: 22829269
Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13
pubmed: 23334069
Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23
pubmed: 23334070
Ann Neurol. 2013 Apr;73(4):529-36
pubmed: 23424091
Ann Neurol. 2013 Apr;73(4):449-58
pubmed: 23625526
Neurology. 2013 Nov 5;81(19):1659-65
pubmed: 24097810
Int J Clin Pharmacol Ther. 2013 Dec;51(12):911-23
pubmed: 24131736
J Stroke. 2015 Jan;17(1):17-30
pubmed: 25692104
Brain. 2016 Feb;139(Pt 2):563-77
pubmed: 26493635
Neuroimage Clin. 2016 Mar 03;11:461-467
pubmed: 27104140
Lancet Neurol. 2016 Jul;15(8):811-819
pubmed: 27180034